Literature DB >> 10367787

Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease.

G Akpek1, D McAneny, L Weintraub.   

Abstract

We reviewed our experience in 30 patients with direct Coombs-positive (DAT+) autoimmune hemolytic anemia (AHA) who underwent splenectomy. Twelve patients had idiopathic "warm" AHA (group I) and 18 had AHA associated with systemic diseases (group II). Complete response to splenectomy was defined as having normal hemoglobin and reticulocyte count lasting for at least 6 months without subsequent medical therapy. Subnormal but greater than 50% improvement in these parameters with or without medical therapy was considered to be a partial response. Median age was 64 (23-81) in group I and 68 (23-76) in group II. Median follow-up duration was 18 and 10.9 months, respectively. Nine of 11 (82%) evaluable patients with idiopathic AHA and 3 of 16 (19%) patients with associated disease achieved a complete response. Partial response was obtained in 2 (18%) and 6 (37%) patients in groups I and II, respectively. Both complete-response and overall-response rates were statistically different between two groups (P = 0.001 and 0.02). Postoperative courses of group I patients were uneventful except for one who developed a subphrenic abscess. Five patients in group II developed bacterial infections, which were mostly pneumonias. Our findings indicate that splenectomy is an effective treatment approach with low morbidity and mortality in patients with refractory idiopathic AHA. It should, however, be considered cautiously in AHA patients with underlying systemic diseases because of its decreased efficacy and increased surgical morbidity in this subgroup.

Entities:  

Mesh:

Year:  1999        PMID: 10367787     DOI: 10.1002/(sici)1096-8652(199906)61:2<98::aid-ajh4>3.0.co;2-g

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  19 in total

1.  Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective.

Authors:  Ahmad F Thabet; Mostafa Faisal
Journal:  Indian J Hematol Blood Transfus       Date:  2013-08-15       Impact factor: 0.900

2.  Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Annalisa Condorelli; Maddalena Casale; Paola Giordano; Lucia D Notarangelo; Piero Farruggia; Fiorina Giona; Agostino Nocerino; Silvia Fasoli; Maria L Casciana; Maurizio Miano; Fabio Tucci; Tommaso Casini; Paola Saracco; Wilma Barcellini; Alberto Zanella; Silverio Perrotta; Giovanna Russo
Journal:  Blood Transfus       Date:  2018-04-13       Impact factor: 3.443

Review 3.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

4.  A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults.

Authors:  Rong Fu; Siyang Yan; Xiaoming Wang; Guojin Wang; Wen Qu; Huaquan Wang; Yuhong Wu; Hong Liu; Jia Song; Jin Guan; Limin Xing; Erbao Ruan; Lijuan Li; Hui Liu; Zonghong Shao
Journal:  Int J Hematol       Date:  2016-07-04       Impact factor: 2.490

Review 5.  Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Authors:  Anders Osterborg; Claes Karlsson; Jeanette Lundin
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 6.  Treatment of autoimmune hemolytic anemias.

Authors:  Alberto Zanella; Wilma Barcellini
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

Review 7.  Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors:  Zhengrui Xiao; Irina Murakhovskaya
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

Review 8.  A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis.

Authors:  Themistoklis Vassiliadis; Vassilia Garipidou; Vassilios Perifanis; Konstantinos Tziomalos; Olga Giouleme; Kalliopi Patsiaoura; Michalis Avramidis; Nikolaos Nikolaidis; Sofia Vakalopoulou; Ioannis Tsitouridis; Antonios Antoniadis; Panagiotis Semertzidis; Anna Kioumi; Evangelos Premetis; Nikolaos Eugenidis
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 9.  Autoimmunity and Primary Immunodeficiency Disorders.

Authors:  Eric Allenspach; Troy R Torgerson
Journal:  J Clin Immunol       Date:  2016-05-23       Impact factor: 8.317

10.  The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Simona Sica; Dimitar G Efremov
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.